Key points
• Tyrosine kinase inhibitor resistance can be caused by the action of tyrosine kinase inhibitors on mesenchymal stem cells.
• Inhibition of the IL-7R/JAK pathway diminishes tyrosine kinase inhibitor resistance in mesenchymal stem cell milieu. 
Introduction
In Philadelphia chromosome-positive (Ph + ) acute lymphoblastic leukemia (ALL), which is mediated by the BCR-ABL fusion oncoprotein, resistance to the ABL kinase inhibitors can arise from both BCR-ABL-independent and BCR-ABL-dependent mechanisms.
1,2
The BCR-ABL-independent mechanisms consist of extra-chromosomal abnormalities, disruptions in drug intake and efflux, and activation of alternative signaling pathways.
2,3
The BCR-ABL-dependent mechanisms, including mutations in the ABL kinase domain (such as T315I) and amplification of the BCR-ABL gene, 4 usually develop following an initial response to tyrosine kinase inhibitor (TKI) treatment. 5 Overcoming BCR-ABLindependent resistance to TKIs is expected to eliminate leukemic cells early in the disease course and to greatly reduce the occurrence of BCR-ABL-dependent resistance. Recent studies showed that the bone marrow milieu, which includes mesenchymal stem cells (MSCs), may play an essential role in the activation of an alternative survival signaling pathway in leukemic cells that protects leukemic cells from chemotherapy. [6] [7] [8] [9] [10] However, the origin of this resistance in the complex leukemic microenvironment has not been identified. In this study, we used a p190 BCR-ABLtransformed mouse B-cell ALL model to investigate the cascade of events causing the resistance of BCR-ABL-positive (BCR-ABL + ) ALL cells to TKIs.
Methods

Animal studies
All mouse experiments were reviewed and approved by the Institutional Animal Care and Use
Committee of The University of Texas MD Anderson Cancer Center. Details of leukemic cell transplantation, bioluminescence imaging, and TKI dosage are provided in the online supplemental materials.
Viral vectors, transduction, and cell culture
Details of the viral vector construction, virus transduction, and conditions used for culturing
MSCs and leukemic cells are described in the online supplemental materials.
Microscopy
For personal use only. on October 4, 2017. by guest www.bloodjournal.org From Phase contrast and mCherry fluorescence images of cultured cells were taken using an Axio Observer.Z1 microscope, an AxioCam MR camera, and the AxioVision software (Zeiss, Jena, Germany). Total number of leukemic cell clusters (defined as more than 10 leukemic cells) underneath MSCs was obtained from images taken from 10 different fields (10x objective).
Gene expression microarray analysis
Gene expression profiling analysis was performed as described previously. 11 Details of the analysis are provided in the online supplemental materials.
Results and Discussion
In co-cultures of the mouse primary MSC line OP9 (Supplemental Figure 1) and mouse ALL cells (also referred to as unselected leukemic cells (USLCs)) (Supplemental Figure   2A -B), we observed that the ALL cells closely clustered underneath the OP9 cells in the presence of the BCR-ABL prototype inhibitor imatinib (IM), 12, 13 whereas the number of cell clusters was significantly reduced in the absence of IM ( Figure 1A Figure 17D- Here, we suggest that the cascade of events that lead to the development of resistance to TKIs is triggered by TKI therapy itself. At the initial stages of the development of this resistance, MSCs exposed to TKIs become less proliferative and undergo dramatic morphological and molecular changes, leading to the elevated production of chemo-attractants, adhesion molecules, and pro-survival factors.
Stepwise actions of these molecular cues culminate in the initiation of stable interactions, i.e., ALL cell cluster formation beneath the MSCs and the emergence of 
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